Findor J A, Sorda J A, Igartua E B, Avagnina A
División de Gastroenterología, Hospital de Clínicas José de San Martín, Facultad de Medicina, Universidad de Buenos Aires, Argentina.
Medicina (B Aires). 1998;58(3):277-81.
Five cases (four females, one male) of ketoconazole-related liver damage are presented, two of whom died. All patients received ketoconazole (400 mg/day) for various mycoses. In the four women the first signs of hepatotoxicity appeared after four weeks of therapy. One fatal case developed massive necrosis with fulminant liver failure and the other, submassive necrosis. In four cases cholestasis was a prominent finding. Biochemical evidence of biliary stasis may persist for several months, as occurred in the three surviving patients of our series. The two fatal cases continued receiving the drug in spite of its adverse effects. Consequently, repeated evaluation is recommended to detect early signs of liver environment.
本文报告了5例(4例女性,1例男性)酮康唑相关肝损害病例,其中2例死亡。所有患者均因各种真菌病接受酮康唑治疗(400mg/天)。4名女性在治疗4周后出现肝毒性的最初迹象。1例致命病例发生了大块坏死伴暴发性肝衰竭,另1例为亚大块坏死。4例中胆汁淤积是突出表现。胆汁淤积的生化证据可能持续数月,如我们系列中的3名存活患者那样。尽管有不良反应,2例致命病例仍继续用药。因此,建议进行反复评估以发现肝脏损害的早期迹象。